- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
- Interventions
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
- Biological · Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,346
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
- Interventions
- Minnelide™Capsules
- Drug
- Lead sponsor
- Minneamrita Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more
- Conditions
- Pancreatic Cancer
- Interventions
- ISIS 2503, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 13 more
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- dasatinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Colorectal Cancer
- Interventions
- FOLFIRI, RO5083945, cetuximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 16
- States / cities
- Encinitas, California • Highland, California • La Jolla, California + 11 more
- Conditions
- Liver Cancer
- Interventions
- whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pancreatic Cancer
- Interventions
- rhuMAB-VEGF, docetaxel
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
- Interventions
- 177Lu-J591
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Liver Neoplasms
- Interventions
- rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM, rF-CEA(6D)/TRICOM, Recombinant Fowlpox-GM-CSF, Celecoxib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- MRTX849
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 651
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- cisplatin, irinotecan hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide, Laboratory Biomarker Analysis, Pembrolizumab
- Biological · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neoplasms
- Interventions
- TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 64
- States / cities
- Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
- Conditions
- Metastatic Biliary Tract Carcinoma
- Interventions
- Regorafenib
- Drug
- Lead sponsor
- Nathan Bahary, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
- Interventions
- NUV-868, Olaparib, Enzalutamide
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer
- Interventions
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Duarte, California • Denver, Colorado + 13 more
- Conditions
- Pancreas Cancer, Metastatic, Pancreas Carcinoma
- Interventions
- STRONG intervention App, individualized remote dietitian
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
- Interventions
- Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreas Cancer
- Interventions
- Pemigatinib 4.5 MG
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage III Colon Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
- Interventions
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pertuzumab, Trastuzumab, HER-2 testing
- Biological · Drug · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 786
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more
- Conditions
- Colorectal Cancer
- Interventions
- Axitinib, Bevacizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 12
- States / cities
- Jonesboro, Arkansas • Fort Myers, Florida • Pensacola, Florida + 9 more
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- irinotecan hydrochloride, leucovorin calcium, fluorouracil, bevacizumab, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, laboratory biomarker analysis
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California